Oral MRX-1024

Phase 1Small molecule

SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oral MRX-1024 is one of 69 small molecule programs targeting Liposarcoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LiposarcomaActive, not recruiting

Squamous Cell CarcinomaActive, not recruiting

LiposarcomaPhase 1

Active, not recruiting

Squamous Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

20 2

Taxol

Teva

Phase 3

11 3

Tecentriq

Roche

Phase 3

6 4

Paraplatin

AAvyxa

Phase 3

19 5

Libtayo

Regeneron

Phase 3

5 6

Yervoy

Bristol-Myers Squibb

Phase 3

4 7

Vectibix

Amgen

Phase 3

3 8

Beyfortus

BeiGene

Phase 3

2 9

Gilotrif

Boehringer Ingelheim

Phase 3

10 10

Tarceva

DDutch Society of Physicians for Pulmonology and Tuberculosis

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

MRX, Radiation, and Chemotherapy for Patients With Resected Squamous Cell Carcinoma of the Head and Neck

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT00427102

Liposarcoma1 trial

A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Virally Mediated Cancers and Liposarcoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT01537744·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Oral MRX-1024. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Oral MRX-1024 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Oral MRX-1024. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Oral MRX-1024

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Squamous Cell Carcinoma1 trial

Liposarcoma1 trial

References

Drug Info

Quick Facts

Related News